Astellas Pharma has promoted Geoff Towle to vice president, Oncology Marketing, Astellas US.

In his new role, Towle will be responsible for building Astellas Oncology brands with customers in large and specialty market segments through the development and implementation of innovative marketing methods. Towle will report to Mark Reisenauer, senior vice president, Oncology Business Unit.

Photo 1.0: Geoff Towle has been promoted to vice president, Oncology Marketing, Astellas.

“Astellas is committed to making a difference in the lives of cancer patients through an emphasis on innovation and R&D,” Reisenauer said.

“I am confident that Geoff’s proven experience leading pipeline and in-line oncology brands in the US and globally across numerous tumors and other therapeutic areas will help Astellas continue reach its commercial goals, while always keeping patient needs at the center,” he added.

Previously, Towle served as senior director, Oncology Marketing at Astellas, where he led the development of brand strategies, messaging and tactics for enzalutamide (Xtandi?) a nonsteroidal antiandrogen medication, for the treatment of non-metastatic castration-resistant prostate cancer and metastatic (CRPC)

Advertisement #3

Since joining the company in 2011, Towle led four best-in-class launches that have been highlighted within Astellas and across the industry based on speed of execution, quality, and performance. Prior to Astellas, Towle served in a variety of positions with increasing responsibility at Abbott Laboratories, Inc. (now AbbVie).

Towle holds a bachelor’s in management from Bryant University and a master’s in business administration from the University of Michigan.

Last Editorial Review: September 18, 2018

Featured Image: Appointment. Courtesy: ? 2010 ? 2018 Fotolia. Used with permission.

Copyright ? 2010 ? 2018 Sunvalley Communication, LLC. All rights reserved. Republication or redistribution of Sunvalley Communication content, including by framing or similar means, is expressly prohibited without the prior written consent of Sunvalley Communication. Sunvalley Communication shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Onco?Zine, Oncozine and The Onco?Zine Brief are registered trademarks and trademarks of Sunvalley Communication around the world.

Advertisement #5